Date | Title | Description | |
---|---|---|---|
08 May 2025 | On business and financial situation | The Company releases the press release related to the first three months of 2025 financial results | Download |
08 May 2025 | On business and financial situation | The Company releases the first three months 2025 financial results presentation | Download |
08 May 2025 | Announcement of General Shareholders’ Meeting | The Company announces the call of its 2025 Ordinary General Shareholders' Meeting | Download |
08 May 2025 | On business and financial situation | ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID) | Download |
04 Apr 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2025 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Jul 2019 | R&D: new licenses, patents and registered trademarks | ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. | Download |
02 Jul 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2019 | Download |
26 Jun 2019 | Información sobre dividendos | The Company informs about the dividends payment | Download |
12 Jun 2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | Download |
08 May 2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its 2019 General Shareholders Meeting | Download |